Alport Syndrome Market to Grow at a Tremendous 47% CAGR Through 2036, Driven by Emerging Therapies and Expanding Clinical Pipeline | DelveInsight
The Alport syndrome market is expected to witness significant growth over the coming years, driven by advancements in genetic diagnostics, increasing disease awareness, and the introduction of targeted therapies such as ELX-02 (Exaluren) (Eloxx Pharmaceuticals), Vonafexor (Enyo Pharma), BAY3401016 (Evotec and Bayer), Setanaxib (Asahi Kasei), Atrasentan (VANRAFIA) [Novartis (Chinook Therapeutics)], and others.
LAS VEGAS, July 14, 2026 /PRNewswire/ -- Recently published Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Alport Syndrome Market Summary
Discover Alport syndrome new treatment @ https://www.delveinsight.com/report-store/alport-syndrome-market
Key Factors Driving the Growth of the Alport Syndrome Market
Download the report to understand the top emerging Alport syndrome gene therapy @ Alport Syndrome Clinical Trials
As per Aparna Thakur, Project Manager of Forecasting at DelveInsight, ELX-02 is expected to garner the first mover advantage in Alport syndrome, apart from being the first gene therapy with reduced frequency of administration (8 weeks).
DelveInsight's Alport Syndrome Market Report delivers executive-level intelligence on the evolving market landscape, integrating epidemiology, treatment practices, competitive dynamics, emerging therapies, and market forecasts across the major markets through 2034. Built on a rigorous methodology combining comprehensive secondary research, primary interviews with key opinion leaders and industry experts, and proprietary patient-based forecasting models, the report provides a reliable foundation for strategic planning. Designed for pharmaceutical and biotech executives, it enables informed decisions on portfolio strategy, business development, market entry, investment prioritization, and commercial planning.
Alport Syndrome Market Analysis
Alport Syndrome Competitive Landscape
Some of the Alport syndrome medications under development include ELX-02 (Exaluren) (Eloxx Pharmaceuticals), Vonafexor (Enyo Pharma), BAY3401016 (Evotec and Bayer), Setanaxib (Asahi Kasei), Atrasentan (VANRAFIA) [Novartis (Chinook Therapeutics)], Sparsentan (FILSPARI) (Travere Therapeutics and Renalys Pharma), VAR 200 (ZyVersa Therapeutics), R3R01 (River 3 Renal and Bain Capital Life Sciences), and others.
Enyo Pharma's Vonafexor is a once-daily, orally administered, non-bile acid farnesoid X receptor (FXR) agonist engineered with a distinctive chemical scaffold that enhances kidney-targeted delivery. By modulating metabolic, inflammatory, and fibrotic signaling pathways, the therapy is intended to address the underlying mechanisms of renal damage and extracellular matrix remodeling associated with kidney disease.
Eloxx Pharmaceuticals' ELX-02 is a synthetic aminoglycoside designed to restore the production of full-length, functional proteins in diseases caused by nonsense mutations. Administered via subcutaneous or inhalational routes, ELX-02 promotes ribosomal read-through of premature termination codons (PTCs), enabling the synthesis of functional proteins. The therapy targets the CFTR protein, while preclinical studies have also demonstrated its potential in genetic kidney disorders driven by nonsense mutations. ELX-02 is currently being evaluated in a Phase II clinical trial (NCT05448755) for the treatment of Alport syndrome in patients harboring nonsense mutations.
Asahi Kasei's Setanaxib is an investigational dual NADPH oxidase (NOX) inhibitor that selectively inhibits NOX4 and NOX1, enzymes that are overexpressed in cancer-associated fibroblasts and implicated in fibrotic disease processes. The therapy is currently undergoing a Phase II proof-of-concept study for Alport syndrome. In recognition of its potential, both the U.S. FDA and the European Medicines Agency (EMA) granted orphan drug designation for the treatment of Alport syndrome in September and October 2023, respectively.
Evotec and Bayer's BAY3401016 is a monoclonal antibody directed against Semaphorin 3A (Sema3A), an extracellular guidance protein that plays a critical role in regulating the actin cytoskeleton. Disruption of the actin cytoskeleton, particularly within podocytes, is a hallmark of Alport syndrome pathology. Because Sema3A expression is elevated in injured kidneys and contributes to the progression of acute and chronic kidney disease, BAY3401016 is being developed as a potential first-in-class therapy for Alport syndrome. The treatment aims to slow disease progression, delay the onset of end-stage renal disease, and potentially improve associated hearing impairment. The candidate is currently in Phase II clinical development through a collaboration between Bayer and Evotec.
The anticipated launch of these emerging therapies are poised to transform the Alport syndrome market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Alport syndrome market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which pipeline drugs could transform Alport syndrome treatment @ Alport Syndrome Medicaltions
Recent Developments in the Alport Syndrome Market
Alport Syndrome Epidemiology Segmentation
The Alport syndrome epidemiology section provides insights into the historical and current Alport syndrome patient pool and forecasted trends for the leading markets. XLAS continues to represent the largest proportion of diagnosed cases; however, recognition of autosomal dominant and digenic forms is expanding, reshaping epidemiological distribution patterns.
The Alport syndrome treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Alport Syndrome Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Alport Syndrome Market CAGR
47 %
Alport Syndrome Market Size in 2025
USD 27 Million
Key Alport Syndrome Companies
Eloxx Pharmaceuticals, Enyo Pharma, Evotec, Bayer, Asahi Kasei, Novartis (Chinook Therapeutics), Travere Therapeutics, Renalys Pharma, ZyVersa Therapeutics, River 3 Renal, Bain Capital Life Sciences, and others
Key Alport Syndrome Therapies
ELX-02 (Exaluren), Vonafexor, BAY3401016, Setanaxib, Atrasentan (VANRAFIA), Sparsentan (FILSPARI), VAR 200, R3R01, and others
Scope of the Alport Syndrome Market Report
Table of Contents
1
Alport Syndrome Market Key Insights
2
Alport Syndrome Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Methodology
6
Alport Syndrome Market Overview at a Glance
6.1
Emerging Landscape Analysis (by Molecule Type, Phase, and Route of Administration [RoA])
6.2
Market Share of Alport Syndrome by Therapies (%) in the 7MM in 2025
6.3
Market Share of Alport Syndrome by Therapies (%) in the 7MM in 2036
7
Disease Background and Overview
7.1
Introduction
7.2
Types of Alport Syndrome
7.3
Signs and Symptoms
7.4
Causes of Alport Syndrome
7.5
Pathophysiology of Alport Syndrome
7.6
Diagnosis of Alport Syndrome
7.7
Treatment of Alport Syndrome
7.8
Diagnostic and Treatment Guidelines
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumption and Rationale
8.3
Total Prevalent Cases of Alport Syndrome in the 7MM
8.4
Total Diagnosed Prevalent Cases of Alport Syndrome in the 7MM
8.5
The United States
8.5.1
Total Diagnosed Prevalent Cases of Alport Syndrome in the United States
8.5.2
Age-specific Diagnosed Prevalent Cases of Alport Syndrome in the United States
8.5.3
Type-specific Diagnosed Prevalent Cases of Alport Syndrome in the United States
8.5.4
Mutation-specific Diagnosed Prevalent Cases of Alport Syndrome in the United States
8.5.5
Total Treated Cases of Alport Syndrome in the United States
8.6
EU4 and the UK
8.7
Japan
9
Patient Journey
10
Emerging Alport Syndrome Therapies
10.1
Competitive Landscape: Emerging Therapies
10.2
ELX-02 (Exaluren): Eloxx Pharmaceuticals
10.2.1
Product Description
10.2.2
Other Developmental Activity
10.2.3
Clinical Development
10.2.3.1
Clinical Trials Information
10.2.4
Safety and Efficacy
10.2.5
Analyst Views
10.3
Vonafexor: Enyo Pharma
10.4
BAY3401016: Evotec and Bayer
10.5
Setanaxib: Asahi Kasei
10.6
Atrasentan (VANRAFIA): Novartis (Chinook Therapeutics)
10.7
Sparsentan (FILSPARI): Travere Therapeutics and Renalys Pharma
11
Alport Syndrome: Seven Major Market Analysis
11.1
Key Findings
11.2
Market Outlook of Alport Syndrome
11.3
Conjoint Analysis of Alport Syndrome
11.4
Key Market Forecast Assumptions
11.5
Total Market Size of Alport Syndrome in the 7MM
11.6
Total Market Size of Alport Syndrome by Therapies in the 7MM
11.7
The United States Alport Syndrome Market
11.7.1
Total Market Size of Alport Syndrome in the United States
11.7.2
Total Market Size of Alport Syndrome by Therapies in the United States
11.8
EU4 and the UK Alport Syndrome Market
11.9
Japan Alport Syndrome Market
12
Unmet Needs
13
SWOT Analysis
14
KOL Views
15
Market Access and Reimbursement
15.1
The US
15.2
In EU4 and the UK
15.3
Japan
15.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
15.5
Market Access and Reimbursement in Rare Disorders
16
Bibliography
17
Alport Syndrome Market Report Methodology
Related Reports
Alport Syndrome Clinical Trial Analysis
Alport Syndrome Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alport syndrome companies, including Eloxx Pharmaceuticals, Enyo Pharma, Evotec, Bayer, Asahi Kasei, Novartis (Chinook Therapeutics), Travere Therapeutics, Renalys Pharma, ZyVersa Therapeutics, River 3 Renal, Bain Capital Life Sciences, and others.
SGLT Inhibitors Market
SGLT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SGLT inhibitors companies, including Youngene Therapeutics, Jeil Pharmaceuticals, TheracosBio, Eli Lilly, and others.
End-stage Renal Disease Market
End-stage Renal Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ESRD companies, including Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, and others.
Idiopathic Membranous Nephropathy Market
Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IMN companies, including Cerium Pharmaceuticals, Hoffmann-La-Roche, Biogen, BeOne Medicines Ltd., and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP